Measuring function in rheumatoid arthritis - Identifying reversible and irreversible components

被引:242
作者
Aletaha, Daniel
Smolen, Josef
Ward, Michael M.
机构
[1] Med Univ Vienna, Dept Rheumatol, A-1090 Vienna, Austria
[2] NIAMSD, NIH, Bethesda, MD 20892 USA
[3] Hietzing Hosp, Vienna, Austria
来源
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 09期
关键词
D O I
10.1002/art.22052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Measurement of physical function at one point in time cannot distinguish impairment caused by the active disease process from chronic irreversible impairment. We aimed to dissect these two components of functional limitation in rheumatoid arthritis (RA) by using the disability index of the Health Assessment Questionnaire (HAQ) as the measure of function. Methods. We performed a secondary analysis of data from 6 contemporary clinical trials of RA (2,763 patients). Patients in whom remission was achieved in the trials, based on a simplified disease activity index, were identified. In an individual patient, HAQ scores at trial entry represented both reversible and irreversible impairments, while HAQ scores at the time of RA remission represented the mostly irreversible component, and the difference between these corresponded to the component related to disease activity. We tested the concept that the HAQ has a reversible and an irreversible component by associating the HAQ score during remission with 2 measures associated with the degree of accrued damage: duration of RA and radiographic severity. Results. Among patients in whom clinical remission was achieved (n = 295), average HAQ scores despite clinical remission increased progressively with the duration of RA, from 0.19 (< 2 years of RA) to 0.36 (2-< 5 years) to 0.38 (5-< 10 years) to 0.55 (>= 10 years) (P < 0.001). The reversibility of HAQ scores decreased with the duration of RA (median 100%, 83.3%, 81.9%, and 66.7%, respectively; P < 0.001). Findings were similar in patients subgrouped by quartile of radiographic scores. Conclusion. Differences in the sources of functional limitations should be considered in the interpretation of functional measures, and in their use for prediction and in cost analyses.
引用
收藏
页码:2784 / 2792
页数:9
相关论文
共 37 条
  • [21] Scott DL, 2004, J RHEUMATOL, V31, P55
  • [22] SCOTT DL, 1987, LANCET, V1, P1108
  • [23] The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database
    Scott, DL
    Strand, V
    [J]. RHEUMATOLOGY, 2002, 41 (08) : 899 - 909
  • [24] Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine
    Scott, DL
    Smolen, JS
    Kalden, JR
    van de Putte, LBA
    Larsen, A
    Kvien, TK
    Schattenkirchner, M
    Nash, P
    Oed, C
    Loew-Friedrich, I
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (10) : 913 - 923
  • [25] HOW MANY JOINTS IN THE HANDS AND WRISTS SHOULD BE INCLUDED IN A SCORE OF RADIOLOGIC ABNORMALITIES USED TO ASSESS RHEUMATOID-ARTHRITIS
    SHARP, JT
    YOUNG, DY
    BLUHM, GB
    BROOK, A
    BROWER, AC
    CORBETT, M
    DECKER, JL
    GENANT, HK
    GOFTON, JP
    GOODMAN, N
    LARSEN, A
    LIDSKY, MD
    PUSSILA, P
    WEINSTEIN, AS
    WEISSMAN, BN
    [J]. ARTHRITIS AND RHEUMATISM, 1985, 28 (12): : 1326 - 1335
  • [26] A simplified disease activity index for rheumatoid arthritis for use in clinical practice
    Smolen, JS
    Breedveld, FC
    Schiff, MH
    Kalden, JR
    Emery, P
    Eberl, G
    van Riel, PL
    Tugwell, P
    [J]. RHEUMATOLOGY, 2003, 42 (02) : 244 - 257
  • [27] Patients with rheumatoid arthritis in clinical care
    Smolen, JS
    Aletaha, D
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (03) : 221 - 225
  • [28] Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial
    Smolen, JS
    Kalden, JR
    Scott, DL
    Rozman, B
    Kvien, TK
    Larsen, A
    Loew-Friedrich, I
    Oed, C
    Rosenburg, R
    [J]. LANCET, 1999, 353 (9149) : 259 - 266
  • [29] *US DEP HHS FOOD D, GUID IND CLIN DEV PR
  • [30] EFFECTS OF HYDROXYCHLOROQUINE AND SULPHASALAZINE ON PROGRESSION OF JOINT DAMAGE IN RHEUMATOID-ARTHRITIS
    VANDERHEIJDE, DM
    VANRIEL, PL
    GRIBNAU, FW
    NUVERZWART, IH
    VANDEPUTTE, LB
    [J]. LANCET, 1989, 1 (8646) : 1036 - 1038